Current Environment: Production

Medical Services

Programs & Services

Languages

  • English

Education

Medical School

Washington University School of Medicine

1999, St. Louis, MO

Internship

Vanderbilt Children's Hospital

2000, Nashville, TN

Residency

Vanderbilt Children's Hospital

2002, Nashville, TN

Fellowship

Pediatric Infectious Diseases

Lucile Packard Children's Hospital, Stanford University

2006, Stanford, CA

Fellowship

Pediatric Health Services Research

Boston Children’s Hospital and Department of Population Medicine, Harvard Medical School

2009, Boston, MA

Graduate School

MPH

Harvard School of Public Health

2008, Boston, MA

Certifications

  • American Board of Pediatrics (General)
  • American Board of Pediatrics (Infectious Diseases)

Professional History

Dr. Nakamura received her medical degree from Washington University School of Medicine. She completed pediatric residency training at Vanderbilt Children’s Hospital and pediatric infectious diseases fellowship training at Lucile Packard Children’s Hospital at Stanford. She then pursued fellowship training in pediatric health services research at Boston Children’s Hospital and the Department of Population Medicine at Harvard Medical School, during which she received her Master of Public Health degree from Harvard School of Public Health. She joined the Infectious Diseases faculty in 2009.

As Medical Director for the Antimicrobial Stewardship Program, Dr. Nakamura strives to optimize infectious diseases management by improving the safe and judicious use of antimicrobials. She also cares for patients on the General Infectious Diseases and Immunocompromised Host inpatient consult services.

Publications

  1. Strategies, personnel, and diversity of pediatric antimicrobial stewardship programs in the United States: Strategies and composition of US pediatric ASPs. Antimicrob Steward Healthc Epidemiol. 2025; 5(1):e59. View Abstract

  2. Risk Factors for Pediatric Critical COVID-19: A Systematic Review and Meta-Analysis. J Pediatric Infect Dis Soc. 2024 Jul 20; 13(7):352-362. View Abstract

  3. Emergency Department Antibiotic Prescribing for Pediatric Urinary Tract Infections, 2011-2020. Pediatrics. 2024 Jul 01; 154(1). View Abstract

  4. Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients With COVID-19 (September 2022). Clin Infect Dis. 2024 06 27; 78(7):e250-e349. View Abstract

  5. Guidance for prevention and management of COVID-19 in children and adolescents: A consensus statement from the Pediatric Infectious Diseases Society Pediatric COVID-19 Therapies Taskforce. J Pediatric Infect Dis Soc. 2024 Mar 19; 13(3):159-185. View Abstract

  6. Implementation and Perceived Effectiveness of Prospective Audit and Feedback and Preauthorization by US Pediatric Antimicrobial Stewardship Programs. J Pediatric Infect Dis Soc. 2024 Feb 26; 13(2):117-122. View Abstract

  7. An Algorithm to Assess Guideline Concordance of Antibiotic Choice in Community-Acquired Pneumonia. Hosp Pediatr. 2024 02 01; 14(2):137-145. View Abstract

  8. Risk Factors for Pediatric Critical COVID-19: A Systematic Review and Meta-Analysis. medRxiv. 2024 Jan 18. View Abstract

  9. Monoclonal Antibody Use for Coronavirus Disease 2019 in Pediatric Patients: A Multicenter Retrospective Study. J Pediatric Infect Dis Soc. 2023 Apr 18; 12(3):152-155. View Abstract

  10. Digital Antimicrobial Stewardship Decision Support to Improve Antimicrobial Management. Appl Clin Inform. 2023 05; 14(3):418-427. View Abstract

  11. Community-Onset Bacterial Coinfection in Children Critically Ill With Severe Acute Respiratory Syndrome Coronavirus 2 Infection. Open Forum Infect Dis. 2023 Mar; 10(3):ofad122. View Abstract

  12. Impact of a Documented Penicillin Allergy on Antibiotic Selection in Pediatric Patients With Osteomyelitis. Pediatr Infect Dis J. 2023 05 01; 42(5):e140-e142. View Abstract

  13. Life-Threatening Complications of Influenza vs Coronavirus Disease 2019 (COVID-19) in US Children. Clin Infect Dis. 2023 02 08; 76(3):e280-e290. View Abstract

  14. Simultaneous Late, Late-Onset Group B Streptococcal Meningitis in Identical Twins. Clin Pediatr (Phila). 2023 02; 62(2):96-99. View Abstract

  15. Epidemiology and Management of Orbital Cellulitis in Children. J Pediatric Infect Dis Soc. 2022 May 30; 11(5):214-220. View Abstract

  16. Updated Guidance on Use and Prioritization of Monoclonal Antibody Therapy for Treatment of COVID-19 in Adolescents. J Pediatric Infect Dis Soc. 2022 May 30; 11(5):177-185. View Abstract

  17. Immunisation rates and predictors of undervaccination in infants with CHD. Cardiol Young. 2023 Feb; 33(2):242-247. View Abstract

  18. Utility of Broad-Range PCR Sequencing for Infectious Diseases Clinical Decision Making: a Pediatric Center Experience. J Clin Microbiol. 2022 05 18; 60(5):e0243721. View Abstract

  19. Epidemiology and outcomes of invasive aspergillosis among pediatric immunocompromised patients: A 12-year single-center experience. Med Mycol. 2022 Mar 12; 60(4). View Abstract

  20. Comorbidities Associated with Hospitalization and Progression Among Adolescents with Symptomatic Coronavirus Disease 2019. J Pediatr. 2022 06; 245:102-110.e2. View Abstract

  21. Initial Guidance on Use of Monoclonal Antibody Therapy for Treatment of Coronavirus Disease 2019 in Children and Adolescents. J Pediatric Infect Dis Soc. 2021 May 28; 10(5):629-634. View Abstract

  22. Variability in Ceftriaxone Dosing Across 32 US Acute Care Children's Hospitals. J Pediatric Infect Dis Soc. 2021 May 28; 10(5):677-681. View Abstract

  23. Multicenter Interim Guidance on Use of Antivirals for Children With Coronavirus Disease 2019/Severe Acute Respiratory Syndrome Coronavirus 2. J Pediatric Infect Dis Soc. 2021 Feb 13; 10(1):34-48. View Abstract

  24. Multicenter Initial Guidance on Use of Antivirals for Children With Coronavirus Disease 2019/Severe Acute Respiratory Syndrome Coronavirus 2. J Pediatric Infect Dis Soc. 2020 Dec 31; 9(6):701-715. View Abstract

  25. Encouraging Entrustment: A Qualitative Study of Resident Behaviors That Promote Entrustment. Acad Med. 2020 11; 95(11):1718-1725. View Abstract

  26. A Call for Pediatric COVID-19 Clinical Trials. Pediatrics. 2020 08; 146(2). View Abstract

  27. Potential Impact of Initial Clinical Data on Adjustment of Pediatric Readmission Rates. Acad Pediatr. 2019 07; 19(5):589-598. View Abstract

  28. Safety and Tolerability of Moxifloxacin in Children. J Pediatric Infect Dis Soc. 2018 Aug 17; 7(3):e92-e101. View Abstract

  29. Safety of Outpatient Parenteral Antimicrobial Therapy in Children. Pediatr Infect Dis J. 2018 02; 37(2):157-163. View Abstract

  30. Readmission After Pediatric Mental Health Admissions. Pediatrics. 2017 Dec; 140(6). View Abstract

  31. Pediatric Readmissions After Hospitalizations for Lower Respiratory Infections. Pediatrics. 2017 Aug; 140(2). View Abstract

  32. Same-Hospital Readmission Rates as a Measure of Pediatric Quality of Care. JAMA Pediatr. 2015 Oct; 169(10):905-12. View Abstract

  33. Factors associated with meaningful use incentives in children's hospitals. Pediatrics. 2015 Jun; 135(6):e1409-16. View Abstract

  34. Impact of the meaningful use incentive program on electronic health record adoption by US children's hospitals. J Am Med Inform Assoc. 2015 Mar; 22(2):390-8. View Abstract

  35. Measuring pediatric hospital readmission rates to drive quality improvement. Acad Pediatr. 2014 Sep-Oct; 14(5 Suppl):S39-46. View Abstract

  36. Using Medicaid and CHIP claims data to support pediatric quality measurement: lessons from 3 centers of excellence in measure development. Acad Pediatr. 2014 Sep-Oct; 14(5 Suppl):S76-81. View Abstract

  37. Trainee and program director perceptions of quality improvement and patient safety education: preparing for the next accreditation system. Clin Pediatr (Phila). 2014 Nov; 53(13):1248-54. View Abstract

  38. Change in adoption of electronic health records by US children's hospitals. Pediatrics. 2013 May; 131(5):e1563-75. View Abstract

  39. Pediatric readmission prevalence and variability across hospitals. JAMA. 2013 Jan 23; 309(4):372-80. View Abstract

  40. Cost effectiveness of child pneumococcal conjugate vaccination in middle-income countries. Int Health. 2011 Dec; 3(4):270-81. View Abstract

  41. Cost effectiveness of child pneumococcal conjugate vaccination in GAVI-eligible countries. Int Health. 2011 Dec; 3(4):259-69. View Abstract

  42. Electronic health record adoption by children's hospitals in the United States. Arch Pediatr Adolesc Med. 2010 Dec; 164(12):1145-51. View Abstract

  43. Higher prevalence of pharyngeal than nasal Staphylococcus aureus carriage in pediatric intensive care units. J Clin Microbiol. 2010 Aug; 48(8):2957-9. View Abstract

  44. Influenza vaccination in adolescents with high-risk conditions. Pediatrics. 2008 Nov; 122(5):920-8. View Abstract

  45. Pharyngeal carriage of Staphylococcus aureus in pediatric intensive care units. Poster presentation at the Children's Hospital Boston Infectious Diseases Division Research Retreat,. 2008.

  46. Service-oriented architecture for pediatric immunization decision support. Poster presentation at the American Medical Informatics Association Annual Meeting,. 2007.

  47. Service-oriented architecture for pediatric immunization decision support. AMIA Annu Symp Proc. 2007 Oct 11; 1056. View Abstract

  48. Influenza vaccination in adolescents with high-risk conditions. Poster presentation at the Infectious Diseases Society of America Annual Meeting,. 2007.

  49. Influenza vaccination in adolescents with high-risk conditions. Podium presentation at the Annual NRSA Research Trainees Conference,. 2007.

  50. Growth phase- and nutrient limitation-associated transcript abundance regulation in Bordetella pertussis. Infect Immun. 2006 Oct; 74(10):5537-48. View Abstract

  51. Targeting a complex transcriptome: the construction of the mouse full-length cDNA encyclopedia. Genome Res. 2003 Jun; 13(6B):1273-89. View Abstract

  52. Prevalence of methicillin-resistant Staphylococcus aureus nasal carriage in the community pediatric population. Pediatr Infect Dis J. 2002 Oct; 21(10):917-22. View Abstract

Infections affect all of us over the course of our lives. Staying a step ahead of potentially harmful microorganisms is a constant and ever-evolving challenge. As a pediatric infectious diseases specialist, I love teaching patients and families about how we interact with microbes and how to avoid infections. When infectious diseases do occur, I work with patients and families to overcome them so they can get back to their usual activities and passions. I can think of no job more fascinating, rewarding, and meaningful.

BESbswy